Observational data suggest apixaban leads to fewer thromboembolic events but higher bleeding risk, highlighting the need for ...

Study findings highlight the need for increased endoscopic access and optimized medical management to reduce adverse outcomes among patients with CKD hospitalized with angiodysplasia-related ...

A popular drug given to more than a million people since 1993 to limit blood loss during heart surgery doubles a patient's risk of kidney failure and substantially increases the risk of a heart attack ...

Abelacimab reduces major and minor bleeding compared with rivaroxaban for atrial fibrillation -- even in patients with reduced kidney function receiving DOAC dose adjustment. Abelacimab, an ...